Cisplatin-Induced Hearing Loss

Campbell, Kathleen C.M.; Fox, Daniel J.

doi:10.1007/978-3-319-40848-4_6

Cited by 5 publications

(6 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although some guidelines do exist for ototoxicity, none have been universally accepted, and the disagreement between studies is likely the result of many factors, such as administration protocols, treatment cocktails, hearing evaluations and ototoxicity grading methods, cohort sizes, patient ages, and cancer types. 85 Therefore, the design of more uniform studies for future drug development would have a far-reaching impact upon the field. In conclusion, cisplatin-induced ototoxicity can have debilitating effects on a patient’s quality of life, and there is an urgent need to find safe and effective therapies via the development of more efficient drug-delivery methods, combinatorial drug cocktails, or compounds with novel mechanisms of action.…”

Section: Discussionmentioning

confidence: 99%

Progress in the Development of Preventative Drugs for Cisplatin-Induced Hearing Loss

2018

View full text Add to dashboard Cite

Cisplatin is a highly effective treatment for malignant cancers and has become a cornerstone in chemotherapeutic regimens. Unfortunately, its use in the clinic is often coupled with a high incidence of severe hearing loss. Over the past few decades, enormous effort has been put forth to find protective agents that selectively protect against the ototoxic side effects of cisplatin and not interfere with its antitumoral activity. Many therapies have been successful in preclinical work, but only a few have shown any protection in the clinic, and none have been approved by the FDA. This review summarizes the clinical and preclinical studies of the most effective small molecule candidates currently in clinical trials, while also detailing their molecular mechanisms of action, to gain insight for future drug development in the field.

show abstract

Section: Discussionmentioning

confidence: 99%

Progress in the Development of Preventative Drugs for Cisplatin-Induced Hearing Loss

2018

View full text Add to dashboard Cite

show abstract

“…In the majority of the reviewed studies, the assessment of the otoprotective and ototoxic effects involved sensory hair cell counting (eighteen articles). 12 , 17 , 18 , 20 – 22 , 24 , 25 , 27 , 28 , 30 , 31 , 32 – 34 , 39 , 40 An additional method, evaluating the hair cell function, was the uptake of FM1-43 dye (four articles) and the recording of microphonic potentials (two articles). 19 , 21 , 25 , 34 , 43 In six articles, the TUNEL assay was applied, detecting single-stranded brakes in the chromosomal DNA (a feature of apoptosis).…”

Section: Resultsmentioning

confidence: 99%

“…Vlasits et al 12 0-100 µM 24 h Pre-treatment for 1 h, then co-exposure for 24 h Todd et al 5 0-1000 µM 4 h CIS exposure for 4 h Monroe et al 35 100 µM 45 min Co-exposure for 45 min Hong et al 24 1000 µM 4 h Co-exposure for 4 h Lee et al 23 1000 µM 4 h Co-exposure for 4 h Choi et al 42 1000 µM 6 h Co-exposure for 6 h Min et al 26 1000 µM 6 h Pre-treatment for 150 min, then CIS exposure for 6 h Niihori et al 6 1000 μM 4 h Pre-treatment for 12 h, then co-exposure for 4 h Monroe et al 33 100-500 µM 45 min CIS exposure for 45 min,regeneration for 3 h, then coexposure for 15 h (cell culture) Coffin et al 31 250-1000 µM 6 h Pre-treatment for 1 h, then co-exposure for 6 h Uribe et al 18 250-1500 μM 4 h Co-exposure for 4 h Kitcher et al 30 25-200 µM 24 h Co-exposure for 24 h Monroe et al 36 25 mg/kg Single microinjection CIS microinjection, 24 after drug microinjection Mackenzie and Raible 29 50 µM 24 h Co-exposure for 24 h Shin et al 37 50 µM 24 h Pre-treatment for 1 h, then CIS exposure for 24 h Thomas et al 27 50 µM 24 h Pre-treatment for 1 h, then CIS exposure for 24 h Zheng et al 38 50 µM 24 h Pre-treatment for 2 h, then co-exposure for 24 h Hirose et al 22 50 µM 6 h Co-exposure for 6 h Kruger et al 25 500 µM 6 h Co-exposure for 6 h Vargo et al 21 50-200 µM 16 h Co-exposure for 16 h Thomas et al 19 50-500 µM 6 and 24 h Pre-treatment for 1 h, then co-exposure for 6 h and 24 h Rocha-Sanchez et al 34 50-800 µM 6 h Pre-treatment for 2 h, then co-exposure for 6 h Gu et al 39 60 µM 24 h Pre-treatment for 4 h, then CIS exposure for 24 h Pang et al 28 600 µM 12 and 24 h Pre-treatment for 1 h, then co-exposure for 12 h and 24 h Wang et al 40 Data not available 24 h Co-exposure for 24 h and cathepsin were implicated to be involved in apoptotic processes. 44 The therapeutic impact of quinoxaline (Qx) against cisplatin was attributed to the prevention of apoptosis of the sensory hair cells in a still indeterminate way.…”

Section: Duration Of Exposure To Cisplatin Experimental Flowmentioning

confidence: 99%

“…33,35,36 In the studies dedicated to apocynin, L-Serine, CHCP1, Rapamycin, Sal B, KR-22335, ORC-13661, ATX, NAC, CYM-5478, and curcuminoids zebrafish served as a second model in addition to mice, guinea pig, cancer cell lines and HEI-OC1 mouse cell line derived from the organ of Corti. 17,20,27,28,30,35,[38][39][40] The details regarding the experimental design for otoprotective screening are summarized in Table 2.…”

Section: Experimental Protocolsmentioning

confidence: 99%

See 1 more Smart Citation

Use of zebrafish larvae lateral line to study protection against cisplatin-induced ototoxicity: A scoping review

Domarecka

Skarzynska

Szczepek

et al. 2020

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

Aim: The present review aimed to consolidate and analyze the recent information about the use of zebrafish in studies concerning cisplatin-induced ototoxicity and otoprotection. Material and methods: The PubMed, Web of Science, and Scopus databanks were searched using the following MESH terms: zebrafish, cisplatin, ototoxicity. The identified publications were screened according to inclusion and exclusion criteria and the 26 qualifying manuscripts were included in the full-text analysis. The experimental protocols, including cisplatin concentrations, the exposure duration and the outcome measurements used in zebrafish larvae studies, were evaluated and the reported knowledge was summarized. Results: Twenty-six substances protecting from cisplatin-induced toxicity were identified with the use of zebrafish larvae. These substances include quinine, salvianolic acid B, berbamine 6, benzamil, quercetin, dexmedetomidine, dexamethsanone, quinoxaline, edaravone, apocynin, dimethyl sulfoxide, KR-22335, SRT1720, ORC-13661, 3-MA, D-methionine, mdivi-1, FUT-175, rapamycin, Z-LLF-CHO, ATX, NAC, CYM-5478, CHCP1, CHCP2 and leupeptin. The otoprotective effects of compounds were attributed to their anti-ROS, anti-apoptotic and cisplatin uptake-blocking properties. The broadest range of protection was achieved when the experimental flow used preconditioning with an otoprotective compound and later a co-incubation with cisplatin. Protection against a high concentration of cisplatin was observed only in protocols using short exposure times (4 and 6 h). Conclusions: The data extracted from the selected papers confirm that despite the differences between the human and the zebra fish hearing thresholds (as affected by cisplatin), the sensory cells of zebrafish and larval zebrafish are a valuable tool which could be used: (i) for the discovery of novel otoprotective substances and compounds; (ii) to screen their side effects and (iii) to extend the knowledge on the mechanisms of cisplatin-induced inner ear damage. For future studies, the development of a consensus experimental protocol is highly recommended.

show abstract

“…39,40 Within human DIHL research, recent detailed reviews have addressed clinical trials listed in ClinicalTrials.gov 17,41 and strategies for measuring DIHL. 42 Significant ototoxic change (SOC) is defined by the American Speech-Language-Hearing Association (ASHA) and the American Academy of Audiology (AAA) as 20 dB shift at any one test frequency, 10 dB shift at any two consecutive test frequencies, or loss of response at 3 consecutive frequencies where a response was obtained at baseline. 43,44 However, there are multiple other strategies for grading ototoxicity including for example Common Terminology Criteria for Adverse Events (CTCAE) published by the National Cancer Center, the TUNE grading scale, and the Brock, Chang, and International Society of Pediatric Oncology (SIOP) grading scales which are more commonly used for pediatric patients.…”

mentioning

confidence: 99%

Investigational Medicinal Products for the Inner Ear: Review of Clinical Trial Characteristics in ClinicalTrials.gov

Prell

2021

J Am Acad Audiol

View full text Add to dashboard Cite

Background The previous 30 years have provided information on the mechanisms of cell death in the inner ear after noise exposure, ototoxic drug injury, and during aging, and clinical trials have emerged for all of these acquired forms of hearing loss. Sudden hearing loss is less well understood, but restoration of hearing after sudden hearing loss is also a long-standing drug target, typically using steroids as an intervention but with other agents of interest as well. Purpose The purpose of this review was to describe the state of the science regarding clinical testing of investigational medicinal products for the inner ear with respect to treatment or prevention of acquired hearing loss. Data Collection and Analysis Comprehensive search and summary of clinical trials listed in the National Library of Medicine (www.ClinicalTrials.gov) database identified 61 clinical trials. Results Study phase, status, intervention, and primary, secondary, and other outcomes are summarized for studies assessing prevention of noise-induced hearing loss, prevention of drug-induced hearing loss, treatment of stable sensorineural hearing loss, and treatment of sudden sensorineural hearing loss. Conclusion This review provides a comprehensive summary of the state of the science with respect to investigational medicinal products for the inner ear evaluated in human clinical trials, and the current challenges for the field.

show abstract

Cisplatin-Induced Hearing Loss

Cited by 5 publications

References 70 publications

Progress in the Development of Preventative Drugs for Cisplatin-Induced Hearing Loss

Progress in the Development of Preventative Drugs for Cisplatin-Induced Hearing Loss

Use of zebrafish larvae lateral line to study protection against cisplatin-induced ototoxicity: A scoping review

Investigational Medicinal Products for the Inner Ear: Review of Clinical Trial Characteristics in ClinicalTrials.gov

Contact Info

Product

Resources

About